The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus.

A proliferation-inducing ligand B-cell activating factor biomarkers cytokine lupus nephritis systemic lupus erythematosus

Journal

Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265

Informations de publication

Date de publication:
Apr 2022
Historique:
pubmed: 8 3 2022
medline: 8 4 2022
entrez: 7 3 2022
Statut: ppublish

Résumé

We aim to investigate the association between serum B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) levels with disease activity and clinical findings in SLE patients. Seventy-nine patients with SLE and 27 healthy controls were included into the study. Serum BAFF and APRIL levels were measured by using ELISA. In 19 patients with active disease at the time of the assessment, BAFF/APRIL levels were reassessed after 6 months of follow-up and disease activity was evaluated by using SLEDAI-2K. The relationship between renal histopathology index scores and lupus nephritis (LN) classes with serum BAFF/APRIL levels was examined in 16 patients who had recent renal involvement and underwent biopsy during the study. Although both BAFF/APRIL levels were higher in patients with SLE compared to the control group ( These results suggest that both cytokines are involved in the pathogenesis of SLE and that serum BAFF can be valuable as a biomarker in SLE especially in patients with renal activity.

Identifiants

pubmed: 35249405
doi: 10.1177/09612033221086123
doi:

Substances chimiques

B-Cell Activating Factor 0
Biomarkers 0
TNFSF13 protein, human 0
TNFSF13B protein, human 0
Tumor Necrosis Factor Ligand Superfamily Member 13 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

555-564

Auteurs

Selma Sari (S)

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, 37516Istanbul University, Istanbul, Turkey.

Suzan Cinar (S)

Department of Immunology, Aziz Sancar Institute of Experimental Medicine, 37516Istanbul University, Istanbul, Turkey.

Yasemin Yalcinkaya (Y)

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, 37516Istanbul University, Istanbul, Turkey.

Bahar Artim-Esen (B)

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, 37516Istanbul University, Istanbul, Turkey.

Yasemin Ozluk (Y)

Department of Pathology, Istanbul Faculty of Medicine, 37516Istanbul University, Istanbul, Turkey.

Ahmet Gul (A)

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, 37516Istanbul University, Istanbul, Turkey.

Lale Ocal (L)

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, 37516Istanbul University, Istanbul, Turkey.

Günnur Deniz (G)

Department of Immunology, Aziz Sancar Institute of Experimental Medicine, 37516Istanbul University, Istanbul, Turkey.

Murat Inanc (M)

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, 37516Istanbul University, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH